Canada’s drug review agency recommends adding lecanemab, an anti-amyloid antibody, to public drug plans for people with early-stage Alzheimer’s disease, according to multiple outlets. The treatment is designed to target amyloid plaque buildup in the brain, which is widely believed to play a role in the disease’s underlying process. The recommendation applies to patients who meet specified eligibility conditions, although the outlets do not detail those criteria in the provided excerpts. One outlet notes that Health Canada has approved lecanemab, and the drug agency’s recommendation is for public coverage contingent on meeting the program’s requirements. The articles describe lecanemab as a therapy shown to slow the progression of early-stage Alzheimer’s disease, rather than as a cure. The decision reflects an assessment of clinical evidence and the terms under which patients would be able to access the drug through publicly funded plans. Final coverage would depend on how the recommendation is implemented by public drug plan administrators.